Counsel: Exercise caution when relisting in Hong Kong


Chinese companies taken private in the US may consider relisting in Hong Kong as an attractive option, but beware the pitfalls, legal experts involved in the recent WuXi Biologics’ relisting in Hong Kong have warned.

WuXi Biologics recently completed its US$510 million global offering and initial public offering (IPO) on the Main Board of the Stock Exchange of Hong Kong Limited, marking the second Chinese company to relist in Hong Kong after going private in the US.

Compared to re-listing in mainland China, one of the major attractions of Hong Kong is the certainty on timing and procedural transparency, said Colin Law, the head of Greater China and Asia capital markets group team leader at Shearman & Sterling in Hong Kong.

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.